Risk factors for 1‐year mortality in patients with intermediate‐stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization

Lin, Tung-Yi; Huang, Ting-Chang; Lee, Hsi‐Chang; Chen, Kuan-Yang; Liao, Li‐Ying; Wang, Chung-Kwe

doi:10.1016/j.aidm.2013.12.001

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One-year mortality is not rare in individuals with intermediate-stage HCC treated only with TACE. A high blood AFP level (> 400 ng/ml), Child-Pugh B cirrhosis, and tumor size are all independent risk factors for one-year death in such individuals [ 67 ]. Current treatment-related mortality associated with TACE is less than 1%, with acute liver insufficiency being the most common reason for death [ 55 , 58 ].…”

Section: Reviewmentioning

confidence: 99%

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review

Manjunatha¹,

Ganduri²,

Rajasekaran³

et al. 2022

Cureus

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is an aggressive tumor, and even with the breakthrough in preventive strategies, and new diagnostic and treatment modalities, incidence and fatality rates continue to climb. Patients with HCC are most commonly diagnosed in the later stage, where the disease has already advanced, making it impossible to undertake potentially curative surgery. Transarterial chemoembolization (TACE) is a locoregional therapy regarded as a first-line treatment in patients with intermediate-stage HCC (Barcelona clinical liver cancer {BCLC}-B). TACE is a minimally invasive and non-surgical procedure that combines local chemotherapeutic drug administration with embolization to treat HCC. It helps limit tumor growth, preserve liver function, and increase overall and progression-free survival in patients with intermediate-stage HCC. This article has reviewed the efficacy, survival, limitations, and overall benefit of TACE in patients with unresectable HCC. This article has also discussed the effectiveness of TACE for neoadjuvant chemoembolization and the use of TACE with combination therapies.

show abstract

Section: Reviewmentioning

confidence: 99%

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review

Manjunatha¹,

Ganduri²,

Rajasekaran³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…This is of special interest as the majority of HCC patients have underlying liver cirrhosis, and thus inadequate hepatic function increases the risk of severe complications and hepatic decompensation after TACE or TARE [ 8 , 9 ]. Accordingly, acute hepatic failure, which can occur in 3–5% of patients, is one of the most serious complications after TACE [ 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment

Fischer

Wellhöner

Ebel

et al. 2022

Cancers

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are recommended to treat patients with early or intermediate hepatocellular carcinoma (HCC). The liver maximum capacity test (LiMAx) has been supposed to predict the risk of post-interventional liver failure. We investigated the correlation of LiMAx with short-term survival as primary endpoint and the occurrence of adverse events after therapy as secondary endpoint. Our study cohort prospectively included 69 patients receiving TACE (n = 57) or TARE (n = 12). LiMAx test and serological analyses were performed on the day before and 4 weeks after treatment. Hepatic and extrahepatic complications were monitored for 4 weeks. The LiMAx results were not associated with altered liver function and the occurrence of adverse events. The survival rates of patients with BCLC A with LiMAx ≤ 150 μg/kg/h were lower after 30 days (75.0 ± 15.3% vs. 100%, p = 0.011), 90 days (62.5 ± 17.7% vs. 95.8 ± 4.1%, p = 0.011) and 180 days (50.0 ± 17.7% vs. 95.8 ± 4.1%, p = 0.001) compared to those with higher LiMAx levels. The LiMAx test is not suitable to predict liver function abnormalities or the occurrence of complications 4 weeks after therapy but enables the identification of patients with early stage HCC and reduced short-term survival after treatment.

show abstract

Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma

Lin

Lee

et al. 2016

Journal of Cancer Research and Practice

View full text Add to dashboard Cite

Risk factors for 1‐year mortality in patients with intermediate‐stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization

Cited by 4 publications

References 28 publications

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review

The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment

Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma

Contact Info

Product

Resources

About